v3.25.2
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Summary of Loss Before Income Taxes
The Company is subject to taxation in the United States,
China
, Hong Kong, Australia, and Singapore. Loss before income taxes was as follows (in thousands):
 
    
Year Ended
December 31,
 
    
2024
    
2023
 
U.S. operations (domestic)
   $ 7,941      $ 11,280  
Non-U.S.
operations (foreign)
     28,614        9,588  
 
 
 
 
 
 
 
 
 
Loss before provision for income taxes
   $ 36,555      $ 20,868  
 
 
 
 
 
 
 
 
 
Summary of Components of Income Tax Expense
The significant components of the provision for income taxes are as follows:
 
    
Year Ended
December 31,
 
    
2024
    
2023
 
Current expense:
     
Federal
   $ —       $ 221  
State
     13        19  
Foreign
     —         40  
Total current expense:
     13        280  
Deferred expense:
     
Federal
     —         —   
State
     —         —   
Foreign
     —         —   
Total deferred expense:
     —         —   
Total income tax provision:
   $ 13      $ 280  
 
 
 
 
 
 
 
 
 
Summary of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate
A reconciliation of the provision for income taxes to the amount computed by applying the statutory federal income tax rate to the net loss is summarized as follows (in thousands):
 
    
Year Ended
December 31,
 
    
2024
   
2023
 
Domestic statutory rate
     21     21
Foreign rate differential
     (9 )%      4
China R&D deduction
     0     12
Nondeductible expenses
     (1 )%      0
Non-deductible
intellectual property rights
     0     6
Tax credits
     1     2
Change in valuation allowance
     (12 )%      (46 )% 
 
 
 
 
 
 
 
 
 
Total
     0     (1 )% 
 
 
 
 
 
 
 
 
 
Summary of Total Deferred Tax Assets The significant components of the Company’s deferred tax assets and liabilities for the years ended December 31, 2024 and 2023 are shown below (in thousands):
 
    
Year Ended
December 31,
 
    
2024
    
2023
 
Deferred tax assets
     
Net operating losses
   $ 26,334      $ 23,957  
Intellectual property sale
     3,405        3,405  
Capitalized R&D
     4,185        2,915  
Other
     994        438  
 
 
 
 
 
 
 
 
 
Total deferred tax assets
     34,918        30,715  
Less: valuation allowance
     (34,779      (30,590
Total net deferred tax assets
     139        125  
Deferred tax liabilities
     
Operating lease
right-of-use
assets
     (139      (58
 
 
 
 
 
 
 
 
 
Other
     —         (67
Total deferred tax liabilities
     (139      (125
 
 
 
 
 
 
 
 
 
Total net deferred taxes
   $ —       $ —   
 
 
 
 
 
 
 
 
 
summary of Company's Net Operating Losses and Tax Credit Carryforwards
The following table summarizes the Company’s net operating losses and tax credit carryforwards by jurisdiction (in thousands):
 
    
Amount at
December 31,

2024
    
Amount at
December 31,

2023
    
Year

expiration

begins
 
Net operating losses:
        
U.S. federal
   $ 1,688      $ —         Indefinite  
U.S. state
     9,084        1,772       
2041
 
Australia
     959        —         Indefinite  
Hong Kong
     920        902        Indefinite  
Other China
     99,555        95,291       
2025
 
Tax credits:
        
U.S. federal
   $ 671      $ 255        2043  
U.S. state
     316        247        Indefinite  
Summary of Changes in Balance of Gross Unrecognized Tax Benefits
The following table summarizes the changes to the Company’s gross unrecognized tax benefits (in thousands):
 
Unrecognized tax benefit
  
Amount
 
Balance at December 31, 2022
   $ 123  
Additions based on tax positions related to the current year
     115  
Additions based on tax positions of prior years
     —   
Reductions for tax positions of prior years
     —   
Settlements
     —   
 
 
 
 
 
Balance at December 31, 2023
     238  
Additions based on tax positions related to the current year
     75  
Additions based on tax positions of prior years
     —   
Reductions for tax positions of prior years
     —   
Settlements
     —   
 
 
 
 
 
Balance at December 31, 2024
   $ 313  
 
 
 
 
 
IKENA ONCOLOGY INC  
Summary of Components of Income Tax Expense
The components of income tax expense (benefit) were as follows (in thousands):
 
    
Year Ended
December 31,
 
    
2024
    
2023
 
Current
     
Federal
   $ 34      $ (237
State
     118        68  
  
 
 
    
 
 
 
Total current provision (benefit)
   $ 152      $ (169
  
 
 
    
 
 
 
Summary of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate
The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company’s loss before income taxes as follows:
 
    
Year Ended
December 31,
 
    
2024
   
2023
 
Tax effected at statutory rate
     21.0     21.0
State taxes
     (0.3     6.4  
Stock compensation
     (1.3     (1.2
Non-deductible
expenses
     (0.9     (0.6
Federal research and development credits
     2.9       4.2  
Other
     (0.1     0.4  
Change in valuation allowance
     (21.6     (30.0
  
 
 
   
 
 
 
Total
     (0.3 )%      0.2
  
 
 
   
 
 
 
Summary of Total Deferred Tax Assets
The Company’s total deferred tax assets are as follows (in thousands):
 
    
December 31,
 
    
2024
    
2023
 
Deferred tax asset:
     
Federal net operating loss carryforward
   $ 40,218      $ 29,529  
State net operating loss carryforward
     13,145        8,581  
R&D credit carryforwards
     16,339        14,589  
Capitalized
start-up
costs
     176        196  
Accruals and reserves
     492        802  
Stock-based compensation
     2,444        2,381  
Lease liability
     2,078        2,934  
Capitalized R&E
     38,007        44,366  
  
 
 
    
 
 
 
Total deferred tax asset
     112,899        103,378  
Deferred tax liability:
     
Fixed assets
   $ (140    $ (603
Right-of-use
asset
     (1,004      (1,554
  
 
 
    
 
 
 
Total deferred tax liability
     (1,144      (2,157
  
 
 
    
 
 
 
Net deferred tax asset and liability before valuation allowance
     111,755        101,221  
Valuation allowance
     (111,755      (101,221
  
 
 
    
 
 
 
Net deferred tax asset
   $ —       $ —   
  
 
 
    
 
 
 
Summary of Changes in Balance of Gross Unrecognized Tax Benefits
The aggregate changes in the balance of gross unrecognized tax benefits were as follows (dollars in thousands):
 
    
Year Ended
December 31,
 
    
2024
    
2023
 
Balance at the beginning of the year
   $ 949      $ —   
Beginning balance adjustment
     —         927  
Increases related to tax positions taken from prior years
     59        22  
  
 
 
    
 
 
 
Ending balance
   $ 1,008      $ 949